PULMATRIX, INC. Lease, Cost
PULMATRIX, INC. (PULM) reported Lease, Cost of $892.00 thousand for the 12-month period ending 2024-12-31, per its S-4/A filed 2026-09-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-09-17
- PULMATRIX, INC. lease, cost for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. lease, cost for the quarter ending 2024-09-30 was $8.00K, a 98.94% decline year-over-year.
- PULMATRIX, INC. lease, cost for the quarter ending 2024-06-30 was $375.00K, a 36.01% decline year-over-year.
- PULMATRIX, INC. lease, cost for the quarter ending 2024-03-31 was $509.00K, a 3.67% increase year-over-year.
- PULMATRIX, INC. lease, cost for fiscal 2023 was $2.35M, a 10.40% increase from fiscal 2022.
- PULMATRIX, INC. lease, cost for fiscal 2022 was $2.13M, a 36.92% increase from fiscal 2021.
- PULMATRIX, INC. lease, cost for fiscal 2021 was $1.55M, a 16.69% increase from fiscal 2020.
- PULMATRIX, INC. lease, cost for fiscal 2020 was $1.33M, a 28.50% increase from fiscal 2019.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-17 | $8.00K derived: sum of 2 quarters · filed 2026-09-17 | $383.00K derived: sum of 3 quarters · filed 2026-09-17 | $892.00K S-4/A · filed 2026-09-17 | |
| 2024-09-30 | $8.00K 10-Q · filed 2024-11-08 | $383.00K derived: sum of 2 quarters · filed 2024-11-08 | $892.00K 10-Q · filed 2024-11-08 | $1.41M derived: sum of 4 quarters · filed 2025-03-21 | |
| 2024-06-30 | $375.00K 10-Q · filed 2024-08-13 | $884.00K 10-Q · filed 2024-08-13 | $1.40M derived: sum of 3 quarters · filed 2025-03-21 | $2.15M derived: sum of 4 quarters · filed 2025-03-21 | |
| 2024-03-31 | $509.00K 10-Q · filed 2024-05-10 | $1.02M derived: sum of 2 quarters · filed 2025-03-21 | $1.78M derived: sum of 3 quarters · filed 2025-03-21 | $2.36M derived: sum of 4 quarters · filed 2025-03-21 | |
| 2023-12-31 | $513.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $1.27M derived: sum of 2 quarters · filed 2025-03-21 | $1.85M derived: sum of 3 quarters · filed 2025-03-21 | $2.35M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $756.00K 10-Q · filed 2024-11-08 | $1.34M derived: sum of 2 quarters · filed 2024-11-08 | $1.83M 10-Q · filed 2024-11-08 | $2.33M derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | $586.00K 10-Q · filed 2024-08-13 | $1.08M 10-Q · filed 2024-08-13 | $1.57M derived: sum of 3 quarters · filed 2024-08-13 | $2.14M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $491.00K 10-Q · filed 2024-05-10 | $988.00K derived: sum of 2 quarters · filed 2024-05-10 | $1.55M derived: sum of 3 quarters · filed 2024-05-10 | $2.05M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $497.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.06M derived: sum of 2 quarters · filed 2024-03-28 | $1.56M derived: sum of 3 quarters · filed 2024-03-28 | $2.13M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $563.00K 10-Q · filed 2023-11-09 | $1.07M derived: sum of 2 quarters · filed 2023-11-09 | $1.63M 10-Q · filed 2023-11-09 | $2.08M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $503.00K 10-Q · filed 2023-08-10 | $1.06M 10-Q · filed 2023-08-10 | $1.52M derived: sum of 3 quarters · filed 2023-08-10 | $1.88M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $561.00K 10-Q · filed 2023-05-12 | $1.02M derived: sum of 2 quarters · filed 2023-05-12 | $1.37M derived: sum of 3 quarters · filed 2023-05-12 | $1.73M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $812.00K derived: sum of 2 quarters · filed 2023-03-30 | $1.17M derived: sum of 3 quarters · filed 2023-03-30 | $1.55M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $356.00K 10-Q · filed 2022-11-10 | $711.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.10M 10-Q · filed 2022-11-10 | $1.46M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $355.00K 10-Q · filed 2022-08-10 | $740.00K 10-Q · filed 2022-08-10 | $1.10M derived: sum of 3 quarters · filed 2022-08-10 | $1.46M derived: sum of 4 quarters · filed 2022-08-10 | |
| 2021-03-31 | $385.00K 10-Q · filed 2022-05-12 | $748.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.11M derived: sum of 3 quarters · filed 2022-05-12 | $1.43M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $721.00K derived: sum of 2 quarters · filed 2022-03-29 | $1.05M derived: sum of 3 quarters · filed 2022-03-29 | $1.33M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $358.00K 10-Q · filed 2021-11-10 | $685.00K derived: sum of 2 quarters · filed 2021-11-10 | $967.00K 10-Q · filed 2021-11-10 | $1.23M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $327.00K 10-Q · filed 2021-08-10 | $609.00K 10-Q · filed 2021-08-10 | $870.00K derived: sum of 3 quarters · filed 2021-08-10 | $1.13M derived: sum of 4 quarters · filed 2021-08-10 | |
| 2020-03-31 | $282.00K 10-Q · filed 2021-05-11 | $543.00K derived: sum of 2 quarters · filed 2021-05-11 | $803.00K derived: sum of 3 quarters · filed 2021-05-11 | $1.06M derived: sum of 4 quarters · filed 2021-05-11 | |
| 2019-12-31 | $261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $521.00K derived: sum of 2 quarters · filed 2021-03-23 | $775.00K derived: sum of 3 quarters · filed 2021-03-23 | $1.03M 10-K · filed 2021-03-23 | $654.00K 10-K · filed 2020-03-26 |
| 2019-09-30 | $260.00K 10-Q · filed 2020-11-12 | $514.00K derived: sum of 2 quarters · filed 2020-11-12 | $774.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $254.00K 10-Q · filed 2020-08-07 | $514.00K 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $260.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |